|
參考文獻 1.Alden ER, Mandelkorn T, Woodrum DE, Wennberg RP, Parks, CR, and Hodson WA. Morbidity and mortality of infants weighing less than 1,000 grams in an intensive care nursery. Pediatrics 1972;50:40-9. 2.Aldridge A, Aranda JV, and Neims AH. Caffeine metabolism in the newborn. Clin Pharmacol Ther 1979;25:447-53. 3.Al-Omran A, and Al-Alaiyan S. Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline preterm infants. Am J Perintol 1997;14:147-9. 4.Anderson JL, Ayres JW, and Hall CA. Potential pharmacokinetic interaction between theophylline and prednisone. Clin Pharmacy 1984;3:187-9. 5.Aranda JV. Letter: Metabolic effect of theophylline in the premature neonate. J Pediatr 1976;89:833-4. 6.Aranda JV, Sitar DS, Parsons WD, Loughnan PM, and Neims AH. Pharmacokinetic aspects of theophylline in premature newborns. N Engl J Med 1976;295:413-6. 7.Aranda JV, Cook CE, Gorman W, Coolinge JM, Loughnan PM, and Outerbridge EW et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr 1979;94:663-8. 8.Aranda JV, Chemtob S, Laudignon N, and Sasyniuk BI. Pharmacologic effects of theophylline in the newborn. J Allergy Clin Immunol 1986;78:773-80. 9.Bairam A, Boutroy M-J, Badonnel Y, and Vert P. Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. J Pediatr 1987;110:636-9. 10.Barbé F, Hansen C, Badonnel Y, Legagneur H, Vert P, and Boutroy M-J. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. Ther Drug Monit 1999;21:547-52. 11.Barett CT, Sevanian A, and Lavin N. Role of adenosine 3’ 5’ monophosphate in maturation of fetal lungs. Pediatr Res 1976;10:621-5. 12.Barrington K, Finer NN, Peter KL, and Barton J. Physiologic effects of doxapram in idiopathic apnea of prematurity. J Pediatr 1986;108:125-9. 13.Barrington K, and Finer N. The natural history of the appearance of apnea of prematurity. Pediatr Res 1991;29:372-5. 14.Barrington KJ, and Finer NN. A randomized controlled trial of aminophylline in ventilatory weaning of premature infants. Crit Care Med 1993;21:846-50. 15.Bednarek FJ, and Roloff DW. Treatment of apnea of prematurity with aminophylline. Pediatrics 1976;58:335-9. 16.Bernstein PS. Conference: Society of maternal-fetal medicine -Risks and benefits of antenatal corticosteroids. 17.Bhatia J. Current options in the management of apnea of prematurity. Clin Pediatr 2000;39:327-36. 18.Bhatt-Mehta V, Johnson CE, Donn SM, Spadoni V, and Schork MA. Accuracy and reliability of dosing equations to individualize theophylline treatment of apnea of prematurity. Pharmacotherapy 1995;15:246-50. 19.Bhatt-Mehta V, Donn SM, Schork A, Reed S, and Johnson CE. Prospective evaluation of two dosing equations for theophylline in premature infants. Pharmacotherapy 1996;16:769-76. 20.Blanchette VS, and Zipursky A. Assessment of anemia in newborn infants. Clin Perinatol 1984;11:489-510. 21.Bonati M, Latini R, Marra G, Assael BM, and Parini R. Theophylline metabolism during the first month of life and development. Pediatr Res 1981;15:304-8. 22.Bower LK, Barnhart SL, Betit P, clink J, Hendon B, Masi-Lynch J, and Wilson BG. Application of continuous positive airway pressure to neonates via nasal prongs or nasopharyngeal tube. AARC clinical practice guideline. Respir Care 1994;39:817-23. 23.Brouard C, Moriette G, Murat I, Flouvat V, Pajot N, and Walti H et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. AJDC 1985;139:689-700. 24.Butcher-P MC, Henderson-S DJ, Holley D, Lacey JL, and Edwards DA. Relation between apnoea duration and type and neurological status of preterm infants. Arch Dis Child 1985;60:953-8. 25.Calhoun LK. Pharmacologic management of apnea of prematurity. J Perinat Neonatal Nurs 1996;9:56-62. 26.Carnielli VP, Verlato G, Benini F, Rossi K, Cavedagni M, and Filippone M et al. Metabolic and respiratory effects of theophylline in the preterm infant. Arch Dis Child Fetal Neonatal Ed 2000;83:F39-43. 27.Cartaya EB, Pathak A, Lhamm C, and Eyal FG. Effect and safety of doxapram. Pediatr Reasearch 1989;25:305A. 28.Chaudhuri M, Garg SK, Narang A, and Bhakoo ON. Kinetics of theophylline in apnea of prematurity in small for gestational age babies. Idian Pediatr 1996;33:181-7. 29.Collart L, Blaschke TF, Boucher F, and Prober CG. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther 1992;18:71-80. 30.Conlon PF, Grambau GR, Johnson CE, and Weg JG. Effect of intravenous furosemide on serum theophylline concentration. Am J Hosp Pharm 1981;38:1345-7. 31.Consensus statement: national institutes of health consensus development conference on infantile apnea and home monitoring, Sept 29 to Oct 1, 1986. Pediatrics 1987;79:292-9. 32.Corbet AJS, Flax P, and Alston C. Effect of aminophylline and dexamethasone on secretion of pulmonary surfactant in fetal rabbits. Pediatr Res 1978;12:797-9. 33.Cordoba E, Gerhardt T, Rojas M, Duara S, and Bancalari E. Comparison of the effects of acetazolamide and aminophylline on apnea incidence and on ventilatory response to CO2 in preterm infants. Peditr Pulmonol 1994;17:291-5. 34.Daily WJ, Klaus M, and Meyer HB. Apnea in premature infants: monitoring, incidence, heart rate changes, and an effect of environmental temperature. Pediatrics 1969;43:510-8. 35.Dani C, Bertini G, Reali M, Tronchin M, Wiechmann L, and Martelli E et al. Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment. Biol Neonate 2000;78:27-32. 36.Davi MJ, Sankaran K, Simons KJ, Simons FR. Seshia MM, and Rigatto H. Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. J Pediatr 1978;92:91-5. 37.Davis P, Doyle L, Rickards A, Kelly E, Ford G, and Davis NM et al. Methylxanthines and sensorineural outcome at 14 years in children < 1501 g birthweight. J Pediatr Child Health 2000;36:47-50. 38.Diderholm B, Ewald U, and Gustafsson J. Effect of theophylline on glucose production and lipolysis in preterm infants (£ 32 weeks). Pediatr Res 1999;45:674-9. 39.Durand DJ, Goodman A, Ray P, Ballard RA, and Clyman RI. Theophylline treatment in the extubation of infants weighing less than 1,250 grams: a controlled trial. Pediatrics 1987;80:684-8. 40.Eichenwald EC, Aina A, and Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Pediatrics 1997;100:354-9. 41.Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM and Wynne BA et al. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy 2000;20:644-52. 42.Ergusson RJ, Scott CM, Rafferty P, and Gaddie J. Effect of prednisolone on theophylline pharmacokinetics in patients with chronic airflow obstruction. Thorax 1987;42:195-8. 43.Fjeld CR, Cole FS, and Bier DM. Energy expenditure, liposis, and glucose production in preterm infants treated with theophylline. Pediatr Res 1992;32:693-8. 44.Gal P, Roop C, Robinson H, and Erkan NV. Theophylline-induced seizures in accidentally overdosed neonates. Pediatrics 1980;65:547-9. 45.Gal P, and Ravenel SD. Editor: Extubation of infants with respiratory distress syndrome using aminophylline. J Pediatr 1984;104:485-6. 46.Gal P, and Gilman JT. Concerns about the food and drug administration guidelines for neonatal theophylline dosing. Ther Drug Monit 1986;8:1-3 47.Gaultier Cl. Apnea and sleep state in newborns and infants. Biol Neonate 1994;65:231-4. 48.Gerhardt T, McCarthy J, and Bancalari E. Effect of aminophylline on respiratory center activity and metabolic rate in premature infants with idiopathic apnea. Pediatrics 1979;63:537-42. 49.Gerhardt T, and Bancalari E. Apnea of prematurity: I. Lung function and regulation of breathing. Pediatrics 1984;58-62. 50.Gilman JT, Gal P, Levine RS, Hersh GB, and Erkan NV. Factors influencing theophylline disposition in 179 newborns. Ther Drug Monit 1986;8:4-10. 51.Gittermann MK, Fusch C, Gittermann AR, Regazzoni BM, and Moessinger AC. Early nasal continuous positive airway pressure treatment reduces the need for intubation in very low birth weight infants. Eur J pediatr 1997;156:384-8. 52.Guennec J-C L, Billon B, and Pare C. Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gesatation age, hepatic disease, and breast-feeding. Pediatrics 1985;76:834-40. 53.Gunn TR, Metrakos K, Riley P, Willis D, and Aranda JV. Sequelae of caffeine treatment in preterm infants with apnea. J Pediatr 1979;94:106-9. 54.Harris MC, Baumgart S, Rooklin AR, and Fox WW. Successful extubation of infants with respiratory distress syndrome using aminophylline. J Pediatr 1983;103:303-5. 55.Hascoet JM, Hamon I, and Boutroy MJ. Risks and benefits of therapies for apnoea in premature infants. Drug Safety 2000;23:363-79. 56.Hendeles L, Massanari M, Weinberger M. Theophylline. In: Evans WE, Schentag JJ, and Jusko WJ. eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Spokane, Applied Therapeutics Inc.;1986:1105-88. 57.Hodgman JE, Gonzalez F, Hoppenbrouwers T, and Cabal LA. Apnea, transient episodes of bradycardia, and periodic breathing in preterm infants. AJDC 1990;144:54-7. 58.Hogue SL, and Phelps ST. Evaluation of three theophylline dosing equations for use in infants up to one year of age. J Pediatr 1993;123:651-6. 59.Holditch-D D, Edwards LJ, and Wigger MC. Pathologic apnea and brief respiratory pauses in preterm infants: relation to sleep state. Nursing Res 1994;43:293-300. 60.Hufnal-M CA, Blackmon L, Baumgart S, and Pereira GR. Enteral theophylline and necrotizing enterocolitis in the low-birthweight infant. Clin Pediatr 1993:647-52. 61.Janicke UA, KrÜdewagen B, Schulz A, and Gundert-R U. Absence of a clinically significant interaction between theophylline and furosemide. Eur J Clin Pharmacol 1987;33:487-91. 62.Jones RA-K. Dosage schedule for intravenous aminophylline in apnoea of prematurity, base on pharmacokinetic studies. Arch Dis Child 1979;54:190-3. 63.Jones RA-K. A controlled trial of a regularly cycled oscillating waterbed and a non-oscillating waterbed in the prevention of apnoea in the perterm infant. Arch Dis Child 1981;56:889-91. 64.Jones RA-K. Apnoea of immaturity: a controlled trial of theophylline and face mask continuous positive airways pressure. Arch Dis Child 1982;57:761-5. 65.Jordan GD, Themelis NJ, Messerly SO, Jarrett RV, Garcia J, and Frank G. Doxapram and potential benzyl alcohol toxicity: a moratorium on clinical ivestigation? Pediatrics 1986;78:540-1. 66.Kandrotas RJ, Cranfield TL, Gal P, Ransom JL, and Weaver RL. Effect of phenobarbtial administration on theophylline clearance in premature neontes. Ther Drug Monit 1990;12:139-43. 67.Karlsson MO, Thomson AH, McGovern EM, Chow P, Evans TJ, and Kelman AW. Population pharmacokinetics rectal theophylline in neonates. Ther Drug Monit 1991;13:195-200. 68.Kattwinkel J, Nearman HS, Fanaroff AA, Katona PG, and Klaus MH. J Pediatr 1975;86:588-92. 69.Khalaf MN, Brodsky N, Hurley J, and Bhandari V. A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation verus nasal continuous positive airway pressure as modes of extubation. Pediatrics 2001;108:13-7. 70.Kitchen WH, Yu VH, Orgill AA, Ford GF, Rickards A, and Astury J et al. Collaborative study of very-low-birth-weight infants. Am J Dis Child 1983;137:555-9. 71.Klesh KW, Brozanski BS, and Guthrie RD. Apnea of prematurity: current theories of pathogenesis and treatment. In: Guthrie RD ed. Neonatal intensive care 1st ed, Churchill Livingstone Inc;1988: 91-122. 72.Korner AF, Kraemer HC, Haffner ME, and Cosper LM. Effects of waterbed flotation on premature infants: a pilot study. Pediatrics 1975;56:361-7. 73.Korner AF, Guilleminault C, Hoed JV, and Baldwin RB. Reduction of sleep apnea and bradycardia in preterm infants on oscillating water beds: a controlled polygraphic study. Pediatrics 1978;61:528-33. 74.Korner AF, Ruppel EM, and Rho JM. Effects of water beds on the sleep and motility of theophylline-treated preterm infants. Pediatrics 1982;70:864-9. 75.Kraus DM, Fischer JH, Reitz SJ, Kecskes SA, Yeh TF, and McCuuloch KM et al. Alteractions in theophylline metabolism during the first year of life. Clin Pharmacol Ther 1993;54:351-9. 76.Kraus DM, Hatzopoulos FK, Reitz SJ, and Fischer JH. Pharmacokinetic evaluation of two theophylline dosing methods for infants. Ther Drug Monit 1994;16:270-6. 77.Krauss AN. Apnea in infancy: pathophysiology, diagnosis, and treatment. NY State J Med 1986;Feb:89-96. 78.Kriter KE, and Blanchard J. Therapy review: management of apnea in infants. Clin Pharm 1989;8:577-87. 79.Kurz H. Influence of nasopharyngeal CPAP on breathing pattern and incidence of apnoeas in preterm infants. Biol Neonate 1999;76:129-33. 80.Kuzemko JA, Paala J. Apnoeic attacks in the newborn treated with aminophylline. Arch Dis Child 1973;48:404-6. 81.Lagercranta H, Rane A, and Tunell R. Plasma concentrations-effect relationship of theophylline in treatment of apnea in preterm infants. Eur J Clin Pharmacol 1980;18:65-8. 82.Lee D, Caces R, Kwiatkowski K, Cates D, and Rigatto H. A developmental study on types and frequency distribution of short apneas(3 to 15 seconds) in term and preterm infants. Pediatr Res 1987;22:344-9. 83.Lee TC, Charles BG, Steer PA, Flenady VJ, and Grant TC. Theophylline population pharmacokinetics form routine monitoring data in very premature infants with apnoea. Br J Clin Pharmacol 1996;41:191-200. 84.Lesko LJ. Dose-dependent kinetics of theophylline. J Allergy Clin Immunol 1986;78:723-7. 85.Lin CH. Wang ST, Lin YJ, and Yeh TF. Efficacy of nasal intermittent positive pressure ventilation in treating apnea of prematurity. Pediatr Pulmonol 1998;26:349-53. 86.Loughnan PM, and Namara JM. Paroxysmal supraventricular tachycardia during theophylline therapy in a premature infant. J Pediatr 1978;92:1016-8. 87.Marchal F, Bairam A, and Vert P. Neonatal apnea and apneic syndromes. Clin Perintol 1987;14:509-29. 88.Marquis JF, Carruthers SG, Spence JD, Brownstone YS, and Toogood JH. Phenytoin-theophylline interaction. N Engl J Med 1981;307:1189-90. 89.McNamara F, and Sullivan CE. Obstructive sleep apnea in infants and its management with nasal continuous positive airway pressure. Chest 1999;116:10-6. 90.Miller CA, Gaylord M, and Lorch M. The use of primidone in neonates with theophylline-resistant apnea. Am J Dis Child 1993;147:183-6. 91.Miller MJ, Carlo WA, and Martin RJ. Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants. J pediatr 1985;106:91-4. 92.Miller MJ, and Martin RJ. Apnea of permaturity. Clin Perinatol 1992;19:789-807. 93.Miller CA, Caylord M, Lorch M. The use of primidone in neonates with neonates with theophylline-resistant apnea. Am J Dis Child 1993;147:183-6. 94.Milner AD, Boon AW, Saunders RA, and Hopkin IE. Upper airways obstuction and apnoea in preterm babies. Arch Dis Child 1980;55:22-5. 95.Moore ES, Faix RG, Banagale RC, and Grasela TH. The population pharmacokinetics of theophylline in neonates and young infants. J Pharmacokin Biopharm 1989;17:47-65. 96.Murat I, Moriette G, Bilin MC, Couchard M, Flouvat B, and Gamarra ED et al. The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. J Pediatr 1981;99:984-9. 97.Murphy JE. New FDA guidelines for therophylline dosing in infants. Clinical pharmacy 1986;5:16. 98.Muttitt SC, Tierney AJ, and Finer NN. The dose response of theophylline in the treatment of apnea of prematurity. J Pediatr 1988;112:115-21. 99.Myers TF, Milsap RL, Krauss AN, Auld PA-M, and Reidenberg MM. Low-dose theophylline therapy in idiopathic apnea of prematurity. J Pediatr 1980;96:99-103. 100. Nassif EG, Weinberger MM, Shannon D, Guiang SF, Hendelex L, and Jimenez D et al. Theophylline disposition in infancy. J Pediatr 1981;98:158-61. 101. Nobel PA, and Light GS. Theophylline-induced diuresis in the neonate. J Pediatr 1977;90:825-6. 102. Papageorgiou A, and Bardin CL. The extremely-low-birth-weight infants: apnea of prematurity. In: Avery GB ed. Neonatology: pathophysiology and management of the newborn. 5th ed. Philadelphia: Lippincott Williams&Wilkins companies;1999:464. 103. Peabody JL, Neese AL, Philip GS, Lucey JF, and Soyka LF. Transcutaneous oxygen monitoring in aminophylline-treated apneic infants. Pediatrics 1978;62:698-701. 104. Peliowski A, and Finer NN. A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. J Pediatr 1990;116:648-53. 105. Persson CA. Overview of effects of theophylline. J Allergy Clin Immunol 1986;78:780-7. 106. Pesce AJ, Rashkin M, and Kotagal U. Standards of laboratory practice: theophylline and caffeine monitoring. Clin Chem 1998;44:1124-8. 107. Powell EC, Reynolds SL, and Rubenstein JS. Theophylline toxicity in children: A retrospective review. Pediatr Emer Care 1993;9:129-3. 108. Preez MJ, Botha JH, McFadyen ML, and Holford NG.The pharmacokinetics of theophylline in premature neonates during the first few days after birth. Ther Drug Monit 1999;21:598-603. 109. Reese J, Prentice G, and Yu VY-H. Dose conversion from aminophylline to theophylline in preterm infants. Arch Dis Child 1994;71:F51-2. 110. Resar RK, Fritz WL, Perry DF, and Barbee RA. Kinetics of theophylline: variability and effect of arterial pH in chronic obstructive lung disease. Chest 1979;76:11-6. 111. Rigatto H, and Brady JP. Periodic breathing and apnea in preterm infants: II. Hypoxia as a primary event. Pediatrics 1972;50:219-27. 112. Rigatto H, Brady JP, and Verduzco R-T. Chemoreceptor reflexes in preterm infants: I. The effect of gestational and postnatal age on the ventilatory response to inhalation of 100% and 15% oxygen. Pediatrics 1975;55:604-13. 113. Rigatto H, Brady JP, and Verduzco R-T. Chemoreceptor reflexes in pretem infants: II. The effect of gestational and postnatal age on the ventilatory response to inhaled carbon dioxide. Pediatrics 1975;55:614-20. 114. Robertson NJ, Hamilton PA. Randomised trial of elective continuous positive airway pressure (CPAP)compared with rescue CPAP after extubation. Arch Dis Child Fetal Neonatal Ed 1998;79:F58-60. 115. Rosenkrantz TS, and Oh W. Aminophylline reduces cerebral blood flow velocity in low birth weight infants. Am J Dis Child 1984;138:489 116. Ruggins NR. Pathophysiology of apnoea in preterm infants. Arch Dis Child 1991;66:70-3. 117. Ryan CA, Finer NN, and Peter KL. Nasal intermittent positive-pressure ventilation offers no advantages over nasal continuous positive airway pressure in apnea of prematurity. AJDC 1989;143:1196-8. 118. Scanlon JM, Chin KC, Morgan MI, Durbin GM, Hale KA, and Brown SS. Caffeine or theophylline for neonatal apnoea?. Arch Dis Child 1992;67:425-8. 119. Schmidt B. Methylxanthine therapy in premature infants: Sound practice, disaster, or fruitless byway?. J Pediatr 1999;135:526-8. 120. Schulte FJ, Busse C, and Eichorn W. Rapid eye movement sleep, motoneurone inhibition, and apneic spells in preterm infants. Pediatr Res 1977;11:709-13. 121. Shannon DC, Gotay F, Stein IM, Rogers MC, Todres ID, and Moylan FM. Pediatrics 1975;55:589-94. 122. Sheiner LB, Rosenberg B, and Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokin Biopharm 1977;5:445-79. 123. Sims ME, Yau G, Rambhatla S, Cabal L, Wu P Y-K. Limitations of theophylline in the treatment of apnea of prematurity. AJDC 1985;139:567-70. 124. Sims ME, Rangasamy R, Lee S, Chung H, Cohen J, and Walther FJ. Coomparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. Am J Perinatol 1989;6:72-5. 125. Stonestreet BS, Nowicki PT, and Hansen NB. Effect of aminophylline on brain blood flow in the newborn piglet. Dev Pharmacol Ther 1983;6:248. 126. Srinivasan G, Pildes RS, and Jaspan JB. Metabolic effects of theophylline in premature infants. J Pediatr 1981;98:815-7. 127. Tatro DS ed. Theophylline-corticosteroids. In: Drug Interaction Facts, St. Louis, Wolters Kluwer company. 2002:1248. 128. Toback JW, and Gilman ME. Theophylline-furosemide inactivation? Pediatrics 1983;71:140-1. 129. Tröger U and Meyer FP. Influence of endogenous and exogenous effectors on the pahrmacokinetics of theophylline. Clin Pharmacolinet 1995;28:287-314. 130. Tserng KY, Takieddine FN, and King KC. Developmental aspects of theophylline metabolism in premature infants. Clin Pharmacol Ther 1983;33:522-8. 131. Tuck SJ, Monin P, Duvivier C, May T, and Vept P. Effect of a rocking bed on apnoea of prematurity. Arch Dis Child 1982;57:475-7. 132. Uauy R, Shapiro DL, Smith B, and Warshaw JB. Pediatrics 1975;55:595-8. 133. Undem BJ and Lichtenstein LM. Drugs used in the treatment of asthma:theophylline. In: Hardman JG and Limbird LE ed. Goodman & Gilman’s the pharmacological basis of therapeutics, 10th ed. McGraw-Hill, New York;2002:743-7. 134. Upton CJ, Milner AD, and Stokes GM. Upper airway patency during apnoea of prematurity. Arch Dis Child 1992;67:419-24. 135. Vallener JJ, Speir WA, Kolbeck RC, Harrison GN, and Bransome ED. Effect of pH on the binding of theophylline to serum proteins. Am Rev Resp Dis 1979;120:83-6. 136. Vassallo R, and Lipsky JJ. Theophylline: Recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin Proc 1998;73:346-54. 137. Vaucher Y, Lightner ES, and Walson PD. Theophylline poisoning. J Pediatr 1977;90:827-30. 138. Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, and Lundstrom K et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 1994;331:1051-5. 140. Viscardi RM, Faix RG, Nicks JJ, and Grasela TH. Efficacy of theophylline for prevention of post-extubation respiratory failure in very low birth weight infants. J Pediatr 1985;107:469-72. 141. Yazdani M, Kissling GE, Tran TH, Gottschalk SK, and Schuth CR. Phenobarbital increases the theophylline requirement of premature infants being treated for apnea. AJDC 1987;141:97-9. 142. Yeh TF. Apnea. In: Neonatal Therapeutics, 2nd ed.St. Louis, MO:Mosby-Year Book, Inc.;1991:40-53. 143. Zanardo V, Dani C, Trevisanuto D, Meneghetti S, Guglielmi A, Zacchello G, Cantaruti F. Methylxanthines increase renal calcium excretion in preterm infants. Biol Neonate 1995;68:169-74. 144. 王文憲 譯,呼吸的控制,人體生理學,合記,第六版pp. 639-52.,1994。 145. 傅祖慶 林富美 林則彬 賴亮全 等人譯,肺換氣的機轉,蓋統生理學-生理及疾病機轉,華杏,第二版,pp.578-83,1995。 146. 洪漢陽及李楫航著,早產兒呼吸暫停,臨床新生兒,嘉洲,第三版,pp157-166,1999。 147. 鄒國英及曹伯年,台灣地區極低出生體重兒之罹病及短期預後,台灣地區早產兒之罹病與死亡情形,中華民國新生兒科醫學會,pp. 1-16,2001
|